# EDGAR Filing Document

**Accession Number:** 0001775194
**File Stem:** 0000000000-25-005975
**Filing Date:** 2025-6
**Character Count:** 3660
**Document Hash:** 4702a898ac3f82e1ba6849d01f586565
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-005975.hdr.sgml**: 20250825

**ACCESSION NUMBER**: 0000000000-25-005975

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250605

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** UPEXI, INC.
- **CENTRAL INDEX KEY:** 0001775194
- **STANDARD INDUSTRIAL CLASSIFICATION:** FINANCE SERVICES [6199]
- **ORGANIZATION NAME:** 09 Crypto Assets
- **EIN:** 833378978
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-287525

**BUSINESS ADDRESS:**
- **STREET 1:** 3030 ROCKY POINT DRIVE
- **STREET 2:** SUITE 420
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607
- **BUSINESS PHONE:** 701-353-5425

**MAIL ADDRESS:**
- **STREET 1:** 3030 ROCKY POINT DRIVE
- **STREET 2:** SUITE 420
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GROVE, INC.
- **DATE OF NAME CHANGE:** 20190429
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001477932-25-004119

## Text-Extract

```

                                                            June 5, 2025

Allan Marshall
Chief Executive Officer
Upexi, Inc.
3030 North Rocky Point Drive, Suite 420
Tampa, FL 33607

       Re: Upexi, Inc.
           Registration Statement on Form S-1
           Filed May 22, 2025
           File No. 333-287525
Dear Allan Marshall:

       We have conducted a limited review of your registration statement and
have the
following comment.

        Please respond to this letter by amending your registration statement
and providing
the requested information. If you do not believe a comment applies to your
facts and
circumstances or do not believe an amendment is appropriate, please tell us why
in your
response.

       After reviewing any amendment to your registration statement and the
information
you provide in response to this letter, we may have additional comments.

Registration Statement on Form S-1
Prospectus Summary, page 3

1.     The prospectus summary should provide a brief overview of the key
aspects of the
       offering. Refer to Regulation S-K, Item 503(a). We note your summary is
limited to a
       discussion of your consumer products business; however, your recent
press releases
       and investor presentations highlight that    the majority of value    is
to come from a
       new treasury strategy that is enabled by the    smaller    nature of
your consumer
       products operations. Accordingly, please revise the summary to reflect
recent events
       and your strategy for creating value. Please also update your risk
factors section to
       discuss the material risks associated with your new treasury strategy.
 June 5, 2025
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence
of action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       Please contact Doris Stacey Gama at 202-551-3188 or Joe McCann at
202-551-6262
with any other questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Peter Campitiello, Esq.

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._